kor kor

큐리진 큐리진

kor kor
Our novel gene therapy approach
incorporates bispecific short hairpin RNA
to silence crucial disease-specific pathways
Bispecific shRNA

Our Bispecific short hairpin RNA technology targets disease causing pathways such as the mTOR (mammalian target of rapamycin) and STAT3 (signal transducer and activator of transcription 3) which are responsible for proliferation and metastasis.

Curigin’s bispecific shRNA is created using a unique gene analysis algorithm to identify areas on target mRNAs that are complimentary to one another. Once the bispecific shRNA is activated, both driver strands silence their target pathways. This leaves no passenger RNA that causes off-target side effects.